US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

LivaNova PLC - Ordinary Shares (NQ:LIVN)

75.07 +0.37 (+0.50%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about LivaNova PLC - Ordinary Shares

< Previous 1 2 3 4 5 Next >
News headline image
LivaNova to Announce Third-Quarter 2026 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Second-Quarter 2026 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Anne Liddy as Chief Legal Officer
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
From LivaNova PLC
Via Business Wire
News headline image
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce First-Quarter 2026 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at J.P. Morgan Healthcare Conference in January
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Piper Sandler Healthcare Conference in December
From LivaNova PLC
Via Business Wire
News headline image
LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Wolfe Research Healthcare Conference in November
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Third-Quarter 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Donald Zurbay as a New Director
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Host Investor Day on November 12, 2025
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Launches Essenz Perfusion System in China
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance
From LivaNova PLC
Via Business Wire
< Previous 1 2 3 4 5 Next >